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IntroductIon
The introduction of antiretroviral therapy (ART) has substantially improved survival in 
people infected with Human Immunodeficiency Virus (HIV). A recent study suggested that 
30% of the 500,000 people living with HIV (PLWHIV) in Europe are now aged over 50 and, 
according to a model by M. Smit et al., dutch PLWHIV aged 50 or older will rise from 28% in 
2010 to 78% in 2030 [1,2]. Despite aging in PLWHIV in Europe and world-wide is quite well 
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AbstrAct
AIM: The aim of the study was to evaluate healthcare resource use and related costs for the management of people living 
with Human Immunodeficiency Virus (PLWHIV) with and without comorbidities, and to compare the burden of comorbidi-
ties in PLWHIV to the general population.
METHODS: An observational retrospective analysis, based on administrative and laboratory databases from 6 Italian Local 
Health Units (LHUs) was performed. Individuals receiving either an HIV treatment [Antiretroviral therapy (ART) – ATC 
code: J05A)], or with an HIV positive laboratory test result between January 1st, 2014 and December 31st, 2014 were 
included. The date of first ART prescription or positive test of HIV was used as the Index Date (ID). Patients enrolled were 
followed-up for all time available from the ID (follow-up period) and their clinical characteristics were investigated from 
one year prior to the ID (characterization period). Comorbidities were measured by using the Charlson Comorbidity Index; 
findings were compared with those of a sample of the general population with the same age and sex distribution (OsMed 
2015). Healthcare resource use and related cost was evaluated during the follow-up period.
RESULTS: 1,214 patients were included, 837 were PLWHIV without any comorbidities and 377 were PLWHIV with at 
least one comorbidity. Mean prevalence of prescriptions for treatment of comorbidities was higher in the HIV-infected 
population than in the Italian general population. The annual healthcare cost of managing HIV patients with comorbidities, 
was significantly higher than that for patients without comorbidities (€ 10,615 vs. € 8,665, p < 0.001).
CONCLUSIONS: Study results showed that 30% of PLWHIV had at least one comorbidity. The cost of managing PLWHIV 
who have comorbidities was significantly higher than that of managing PLWHIV without comorbidities. Our data confirm 
that care and treatment services should be adapted to address the specific needs of people living with both HIV and comor-
bidities. 
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reported [3-5], few Italian data are available [6]. Life expectancy has improved to the extent 
that HIV is increasingly considered a lifelong condition, in which a near-normal lifespan is 
achievable with successful care [3-5]. As a consequence, it’s becoming of increasing interest 
the achievement of good health-related quality of life in PLWHIV, in terms of comorbidities 
and self-perceived quality of life. Studies among cohort of italian PLWHIV investigating the 
quality of life showed that it was lower in patients with older age, with higher number of co-
morbidities, with other drugs prescribed in addition to ART, with coinfection with Hepatitis C 
virus (HCV), and with hospitalization due to HIV [7,8].
HIV has been shown to increase the risk of developing age-related comorbidities, includ-
ing cardiovascular disease, diabetes mellitus, respiratory disease, hepatic diseases and neu-
rocognitive impairments [9]. Moreover, a number of diseases were studied in Italian cohorts 
of PLWHIV and a link between these diseases and increased risk of morbidity and mortality 
was commonly reported. Hypertention has been shown to be highly prevalent among Ital-
ian middle-aged PLWHIV, with a significant impact on cardiovascular mortality [10]; also 
mild renal dysfunction was found to be a relatively frequent condition in an Italian cohort of 
PLWHIV naïve to antiretroviral therapy and this condition was associated to an increased risk 
of cerebro-cardiovascular morbidity and mortality [11]. Another study reported that almost 
one out of four PLWHIW enrolled in an Italian University Hospital had a vertebral fracture, 
which is a complication with a significant prognostic value, and the risk of fractures in this 
cohort was incresed in the elderly, in patients with chronic renal failure and in those with 
previous steroid use [12].
The increased prevalence of non HIV-related complications observed among PLWHIV 
has resulted in increased healthcare costs in comparison to the general population [13,14]. 
Nevertheless, there have been very few studies that have directly evaluated the impact of co-
morbidities in PLWHIV and the relative economic burden on National Healthcare Systems.
The aim of the study was to evaluate healthcare resource use and related costs for the 
management of PLWHIV with and without comorbidities, and to compare the burden of co-
morbidities in PLWHIV to the general population.
Methods
Data Source
The study was conducted using administrative and laboratory databases (DB) of 6 Italian 
Local Health Units (2,249,345 inhabitants, 3.7% of the Italian population) geographically 
distributed throughout the country (50% North, 50% Middle Italy). The structure of these 
DBs have been described in detail elsewhere [15]. In particular, the following DBs were used: 
the Health-Assisted Subjects DB, the Medication Prescription DB, the Hospital Discharge 
DB, the Ambulatory Care Specialist DB and the Laboratory DB. Anonymized data files are 
routinely used by regional health authorities for epidemiological and administrative purposes. 
Informed consent is not required when using encrypted retrospective information. All results 
have been aggregated. Approval was gained from the Ethics Committee of each participat-
ing LHU in accordance with the Italian regulations regarding the conduct of observational 
analyses [16].
Study Population
An observational retrospective cohort analysis was performed. Individuals receiving ei-
ther an HIV treatment (ART, Anatomical Therapeutic Chemical – ATC code: J05A), or with 
an HIV positive laboratory test result between January 1st, 2014 and December 31st, 2014 were 
included. The date of first ART prescription or positive test of HIV (whichever was the earli-
est) during the inclusion period was used as the Index Date (ID).
Individuals enrolled were followed-up for all time available from the ID (follow-up pe-
riod, last available data 31 December 2015) and their clinical characteristics were investigated 
for one year prior to the ID (characterization period). Patients transferred to another LHU 
during the observation period were excluded. History of AIDS-defining events was evalu-
ated in the characterization period according to the Centers for Disease Control classification 
[17]. Comorbidities were identified, as for OsMed report [18], by International Classification 
of Disease (ICD-9-CM) codes of hospitalizations or ATC code of prescribed drugs. The pre-
scription of non HIV-related drugs was used as indicative of the presence of comorbidity: at 
least one prescription of antihypertensive (ATC codes: C02, C03, C07, C08, C09) was consid-
ered as a proxy of hypertension, lipid-lowering agents (ATC code: C10) of dyslipidemia, oral 
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anti-diabetics (ATC code: A10) of diabetes, chronic obstructive pulmonary disease (COPD) 
or asthma medications (ATC code: R03) of COPD/asthma, antirheumatic medications (ATC 
code: M01) for rheumatologic diseases, osteoporosis medications (ATC codes: M05BA, 
M05BB, M05BX, H05AA, H05BA, G06XC) of osteoporosis, antidepressants (ATC code: 
N06A) of depression; antacid or antisecretory agents (ATC code: A02BC) of acid related 
disorders. Cancer diagnosis was identified by ICD9 140-239. Estimated Glomerular Filtration 
Rate (eGFR) was derived by laboratory test and chronic kidney disease was assumed when 
eGFR was less than 60 mL/min. The Charlson Comorbidity Index (CCI) [19] was used to as-
sess each patient’s overall health status; HIV was excluded from CCI analysis.
Drug prescriptions were compared with those of a sample of the general population with 
the same age and sex distribution (OsMed 2015) [18] in particular, rates were calculated as 
number of patients with a specific drug use (e.g. anti-hypertensive) [numerator] over the over-
all sample in the analysis [denominator]; the analyses were stratified for each age class and 
for each gender; these percentages were then compared with the overall population available 
from the OsMed report 2015 [18]. Healthcare resource consumption was evaluated during the 
follow-up period.
Cost analysis
The mean annual healthcare costs per patient were evaluated based on total resource con-
sumption (in term of drugs, hospitalizations, outpatients visit and diagnostic) during the fol-
low-up period. The cost analysis was conducted from the perspective of the Italian National 
Health Service (NHS). Healthcare resource consumption was evaluated during the follow-up 
period; the overall costs are reported in euros (€). Drug costs were evaluated using the actual 
Italian NHS net price. Hospitalization costs were determined using the Diagnosis-Related 
Group (DRG) tariffs.
Statistical analysis
We summarized data as mean and standard deviation (SD) for continuous variables, and 
as numbers and percentages for categorical variables. A generalized regression model giving 
odds ratios (ORs) and 95% confidence intervals (CIs) were used to explore the associations 
between total healthcare costs during the follow-up period and the following variables: age, 
male, and CCI. The variable age was categorized as follows: (i) < 46 years, (ii) 46-65 years, 
(iii) 66-75 years, (iv) ≥ 76 years; the variable CCI was categorized basing on the resulted 
scores as (i) “0”, (ii) “1”, (iii) “2”, (iv) “3”. The model was adjusted for the variable naïve 
(yes/no). P-values < 0.05 were considered to be statistically significant. All analyses were 
performed using STATA 12.0 (StataCorp LP, College Station, TX, USA).
results
Out of the total 2,249,345 individuals recorded in the LHU database, 1,214 patients met 
the inclusion criteria (diagnosis of HIV, defined as ART prescription or positive HIV test), rep-
resenting roughly the 0.05% of the total insured population. Of the 1,214 identified patients 
Total
(n., %)
Cohort HIV only 
(n.,%)
Cohort HIV with comorbidities 
(n.,%)
P-value
N. 1,214 837 377
Age (mean ± SD) 49.4 ± 11.0 48.1 ± 10.9 51.9 ± 11.0 < 0.001
< 46 421 (38) 316 (28) 105 (35) < 0.001
46-65 700 (56) 471 (61) 229 (58) 0.163
66-75 76 (5) 43 (9) 33 (6) 0.023
≥ 76 17 (1) 7 (3) 11 (1) 0.026
≥ 66 93 (6) 50 (12) 44 (7) < 0.001
Male 838 (69) 594 (71) 244 (65) 0.029
CCI (mean ± SD) 0.4 ± 0.8 0.0 ± 0.0 1.4 ± 1.0 /
CCI >1 363 (30) 0 (0) 363 (96) /
AIDS 41 (3) / 41 (11) /
Table I. Demographic and baseline clinical characteristics of patients living with HIV only and HIV with comorbidities
CCI = Charlson Comorbidity Index; SD = Standard Deviation
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available for analysis, 837 were PLWHIV without any comorbidities (cohort: “HIV only”) 
and 377 were PLWHIV with at least one comorbidity (cohort: “HIV with comorbidities”). 
Naïve patients were 251 (20% of our cohort) and 70% of them had no comorbidities.
The mean age of the “HIV with comorbidities” cohort was higher than that of the “HIV 
only” cohort (51.9 vs. 48.1; p < 0.001). The incidence of comorbidities was lower in females. 
Demographic and baseline clinical characteristics are shown in Table I.
The number of comorbidities reported among enrolled patients increased with age. Re-
sults are presented in Figure 1. The most common comorbidities among patients enrolled 
were: hypertension (32.9%), rheumatologic diseases (18.7%), followed by chronic kidney 
disease [defined as eGFR < 60 mL/min, 
from laboratory outcomes database (14%)], 
COPD/asthma (9.2%) and diabetes without 
complications (4.3%) (Figure 2). Mean prev-
alence of prescriptions for treatment of co-
morbidities was higher in the HIV-infected 
population than in the Italian general popula-
tion [18]: anti-hypertensives (+18%), lipid-
lowering agents (+80%), oral anti-diabetics 
(+156%), COPD medications (+122%), os-
teoporosis medications (+17%), anti-depres-
sants (+134%), and antacid or antisecretory 
agents (+52%). For most of the agents, the 
difference was greater in the younger popu-
lation (Figure 3).
The annual healthcare cost of managing 
HIV patients with comorbidities, based on 
resource consumption from ID, was signifi-
cantly higher than that for patients without 
comorbidities: € 10,615 (± 8,425) vs. € 8,665 
(± 5,636); p < 0.001 (Figure 4).Figure 1. Number of comorbidities among PLWHIV  by age class
Figure 2. The most common comorbidities at enrollment in PLWHIV
CKD = Chronic Kidney Disease
1 GFR (Glomerular Filtration Rate) determines the stage of kidney disease. An eGFR below 60 mL/min indicates CKD
eGFR 50-59: mild to moderate loss of kidney function
eGFR 29-49: moderate to severe loss of kidney function
eGFR < 29: severe loss of kidney function
Figure 3. Patients on-treatment for comorbidities in study population versus treatment use in general population
Figure 4. The average annual cost of resources consumption for treating PLWHIV
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Non-HIV-related healthcare costs in PLWHIV increased steadily with the number of co-
morbidities; ranging from € 2,266 (± 6,034) in patients with one comorbidity, to € 4,136 (± 
9,337) with two comorbidities, to over € 5,794 (± 11,837) in patients with three or more co-
morbidities (Figure 5).
The generalized regression model showed that a statistically significant increase in overall 
cost was associated with male gender (aOR = 1,014; 95%CI = 262-1,766; p = 0.008), pres-
ence of one comorbidity (aOR = 1,126; 95%CI = 218-2,033; p = 0.015) and presence of two 
and three comorbidities (aOR = 4,179; 95%CI = 2,050-6,308; p < 0.0001 and aOR = 5,684; 
95%CI = 957-10,411; p = 0.018, respectively) (Table II).
available for analysis, 837 were PLWHIV without any comorbidities (cohort: “HIV only”) 
and 377 were PLWHIV with at least one comorbidity (cohort: “HIV with comorbidities”). 
Naïve patients were 251 (20% of our cohort) and 70% of them had no comorbidities.
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 dIscussIon
The purpose of the study was to provide 
estimates of healthcare resource consump-
tion and related costs for the management of 
PLWHIV with and without comorbidities, 
and to compare the burden of comorbidities 
in PLWHIV to the general population.
In this real-world assessment, around 30% 
of all PLWHIV had at least one comorbidity, 
and their complexity – in terms of number of 
comorbidities – increased with age. Our re-
sults are in agreement with previous analyses 
[1,20,21]. The clinical picture of HIV disease 
has changed rapidly in the last 10 years [2,5]. 
Prolonged exposure to ART and infection 
along with ageing may increase the risk of 
developing non-HIV related comorbidities 
[22]. Indeed, cardiovascular, kidney, liver, 
and cognitive function diseases and malig-
nancies, and metabolic bone disease appear 
to be more common among PLWHIV [23] 
than in the general population.
Several studies have provided evidence 
that PLWHIV with ageing-associated comor-
bidities may require additional pharmaco-
logic interventions that can complicate thera-
peutic management [24-27]. Consistent with 
findings reported in the literature [9,22,28,29] 
older PLWHIV are taking more medications 
to treat comorbidities than younger PLWHIV, 
or similarly-aged HIV-uninfected patients. 
The study also highlights a relationship be-
tween presence of comorbidities and health-
care resource utilization and costs. Our data 
showed that the consumption of non-HIV 
drugs in PLWHIV was higher than in the gen-
eral population. Assuming drug consumption 
as a proxy of comorbidities, the data suggests 
that PLWHIV develop comorbidities earlier, 
and with a higher frequency than the gen-
eral population. This is consistent with the 
expected effect of HIV activity and antiviral 
drugs [30].
A recent European modeling study analyzed future challenges for clinical care of an age-
ing population infected with HIV using a large dataset of HIV-infected patients in Italy [31]. 
The Smit et al. model suggested that the median age of PLWHIV on combination ART will 
increase from 46.1 years in 2015 to 58.8 in 2035, with the proportion PLWHIV aged 50 years 
or older increasing from 30% in 2010 to 76% in 2035. In 2035, researchers have predicted 
that 46% of PLWHIV will have three or more noninfectious comorbidities, up from 19% 
in 2015. Most of this change will be driven by an increasing prevalence of cardiovascular 
disease (hypertension, dyslipidemia, strokes or myocardial infarction), diabetes, and chronic 
kidney disease.
In our descriptive analyses we also observed that healthcare expenditures, based on re-
source consumption from ID, were higher in PLWHIV with comorbidities than in those with-
out comorbidities.
These data are consistent with the results of previous studies [14,22,32,33], suggesting 
that the increasing life expectancy, and the higher prevalence of chronic complications in 
ageing HIV populations play an important role in healthcare costs for HIV management. In 
addition, our data highlights that the costs associated with HIV-related hospitalizations were 
higher in PLWHIV with comorbidities than patients without comorbidities. A recent Italian 
Figure 5. Average annual cost of non-HIV healthcare resources by number of 
comorbidities (p < 0.001)
β 95%CI p
age class
< 46 REF.
46-65 473 -288 1,233 0.223
66-75 -196 -1,734 1,343 0.803
≥ 76 357 -2,892 3,606 0.829
Male 1,014 262 1,766 0.008
Comorbidities (n.)
0 REF.
1 1,126 218 2,033 0.015
2 4,179 2,050 6,308 < 0.0001
3 5,684 957 10,411 0.018
K 7,772 6,996 8,448 0.000
Table II. The overall annual direct cost (€) for treating PLWHIV, Generalized Linear 
Model
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study has investigated the burden of chronic diseases and health costs for PLWHIV compared 
to the general population living in Brescia Local Health Agency over a 12-year period [33]. 
Quiros-Roldan et al. demonstrated an increase of € 3,700 for subjects with at least one chronic 
disease compared to those without. Kidney failure, psychiatric diseases and cancer were the 
most expensive comorbidities, with an increase of per capita cost of € 13,665, € 8,172, and 
€ 7,557, respectively. Studies also confirm that comorbidities can occur by chance, but are 
more often due to the HIV infection and its associated risk factors [20,23,32,33]. Indeed, 
comorbidity increases with HIV severity, and the greater prevalence of comorbidities among 
people living with HIV/AIDS may be attributed to antiretroviral toxicity (diabetes, vascular 
disease and liver disease) or caused by the HIV infection itself (vascular, pulmonary and renal 
diseases) [23].
Our results should be interpreted in the context of some limitations of this study. Our 
cohort of patients reflected real clinical-practice, and interpretation of the results should 
take account of limitations related to the observational nature of the study, based on post-
hoc data collected through administrative and laboratory databases. Since the information 
concerning the comorbidities and the information relative to the severity of the pathology are 
not available, a proxy of the comorbidities was used; this criterion can lead to a bias relative 
to the actual prevalence of the comorbidities (possible underestimation).
conclusIon
Study results showed that 30% of PLWHIV had at least one comorbidity. The number of 
comorbidities increased with age, and the cost of managing PLWHIV who have comorbidities 
was significantly higher than that of managing PLWHIV without comorbidities.
The findings of this study carried out in a real-world setting, highlight the need to manage 
HIV through a multidisciplinary approach, which takes comorbidities into account in addition 
to suppressing viral load. Our data confirm that care and treatment services should be adapted 
to address the specific needs of people living with both HIV and comorbidities.
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